Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naive Adults Without Baseline Genotyping Test (D2ARLING Study)
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms D2ARLING
- 19 Feb 2024 Planned End Date changed from 1 Sep 2023 to 30 Sep 2023.
- 19 Feb 2024 Planned primary completion date changed from 1 Sep 2023 to 30 Sep 2023.
- 02 Jan 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2023.